# HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

> **NCT07629778** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hangzhou Highlightll Pharmaceutical Co., Ltd** · enrollment: 156 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** HL-300
- **DRUG:** Placebo
- **DRUG:** HL-300
- **DRUG:** HL-300

## Key facts

- **NCT ID:** NCT07629778
- **Lead sponsor:** Hangzhou Highlightll Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-26
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629778, "HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07629778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*